veterinary-oncology
(4)
ImpriMed, Inc.
ImpriMed is a Palo Alto-based precision medicine company using live-cell drug sensitivity testing and AI to predict how individual cancer patients - starting with dogs and cats - will respond to specific chemotherapy drugs. Founded in 2017 by Stanford engineering PhDs Sungwon Lim and Jamin Koo, ImpriMed serves a network of 250+ veterinary oncologists and is expanding its platform into human blood cancers and pharma CRO services.
Christina Lopes
Christina Lopes is the CEO and co-founder of The One Health Company, the maker of FidoCure, the first human-grade precision cancer treatment platform for dogs. A former managing director at the $30B private equity firm Cerberus Capital, she left high finance to build a company that sequences canine tumors, matches them with targeted therapies, and feeds the resulting clinico-genomic data back into the fight against human cancer. Born in Brazil and raised across the US and Ireland, she has been named a World Economic Forum Young Global Leader and an Inc. Top 100 Female Founder.
One Health Company (FidoCure)
One Health Company, known to vets and pet parents as FidoCure, brings human-grade precision oncology to dogs. It sequences canine tumors, pinpoints cancer-driving mutations, and uses an AI engine (Fetch) trained on the world's largest structured canine cancer dataset to recommend targeted, FDA-approved therapies. Because dog and human cancers share genetics, the company is also building a comparative-oncology data asset that could accelerate cancer drug development for both species.
Sungwon Lim
Dr. Sungwon Lim is the CEO and Co-Founder of ImpriMed, Inc., a Palo Alto-based precision oncology company that combines live cancer cell testing with AI to predict which drugs will work best for an individual patient's cancer - before treatment begins. Having raised $23M in Series A funding led by SoftBank Ventures Asia, ImpriMed has helped treat over 6,500 dogs with blood cancers across 130+ specialty hospitals in the US, Canada, England, and France, while publishing clinical data showing AI predictions tripled survival rates in relapsed B-cell lymphoma. A Stanford-trained bioengineer inspired by the potential of one powerful medicine to save millions, Lim pioneered a pivot into veterinary oncology as a proving ground before expanding the platform to human cancer treatment.